At a glance
- Originator Sumitomo Pharmaceuticals
- Developer Nonindustrial source; Sumitomo Pharmaceuticals
- Class Analgesics; Butyrates; Neuroprotectants; Nootropics; Tropanes
- Mechanism of Action Acetylcholine stimulants; Sigma-2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dementia; Pain
Most Recent Events
- 25 Mar 2004 Discontinued - Preclinical for Pain in Italy (unspecified route)
- 10 Oct 2003 Discontinued - Preclinical for Dementia in Italy (unspecified route)
- 29 Jun 2001 No-Development-Reported for Dementia in Italy (Unknown route)